Most Specialty Oral Anticancer Meds for Blood Cancers Are Initially Rejected by Insurers

FRIDAY, Oct. 9, 2026-- Access barriers to specialty oral anticancer medications (SOAMs) for blood cancers include rejection by insurance and high out-of-pocket costs, according to a study published online Sept. 30 in the Journal of Clinical...